BioNTech sets survival standard in hard-to-treat cancer
News from Fierce Biotech: BioNTech sets survival standard in hard-to-treat cancer
BioNTech
NASDAQ: BNTX $96.06 USD
BioNTech is a public biotechnology company developing mRNA-based medicines, cancer immunotherapies, infectious-disease vaccines, and antibody-based oncology programs.
Company Info
Sector:mRNA and Immuno-oncology Therapeutics
Headquarters:Mainz, Germany
Founded:2008
Recent News
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
News from BioSpace: Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
BioNTech and Genentech have discontinued their Phase 2 clinical trial testing a personalized cancer vaccine. The decision reflects challenges in the personalized oncology vaccine space.
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
BioNTech and Genentech discontinue a Phase 2 trial of their personalized mRNA cancer vaccine in colorectal cancer.
BioNTech brings in Sobi CEO—Chutes & Ladders
BioNTech brings in Sobi CEO—Chutes & Ladders
BioNTech taps Sobi executive Oelkers as its next CEO
BioNTech taps Sobi executive Oelkers as its next CEO
BioNTech names Guido Oelkers its new CEO
BioNTech has named Guido Oelkers its new CEO, replacing co-founder Ugur Sahin; Oelkers most recently led Swedish biopharma company Sobi.
BioNTech names Sobi's Guido Oelkers as incoming CEO
BioNTech names Sobi CEO Guido Oelkers as its next chief executive, effective by Feb. 1, 2027, as Uğur Şahin exits and the company refocuses on oncology.
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Fierce Pharma reports: BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC.
Leadership Team
Ugur Sahin
Chief Executive Officer
Ozlem Tureci
Chief Medical Officer
Jens Holstein
Chief Financial Officer